Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning

P Fusar-Poli,1,2 F Schultze-Lutter3

1King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK; 2OASIS service, South London and the Maudsley NHS Foundation Trust, London, UK; 3University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland

Correspondence to Dr P Fusar-Poli, Department of Psychosis Studies, Institute of Psychiatry PO63, De Crespigny Park, London SE58AF, UK; paolo.fusar-poli@kcl.ac.uk

ABSTRACT

Prediction of psychosis in patients at clinical high risk (CHR) has become a mainstream focus of clinical and research interest worldwide. When using CHR instruments for clinical purposes, the predicted outcome is but only a probability; and, consequently, any therapeutic action following the assessment is based on probabilistic prognostic reasoning. Yet, probabilistic reasoning makes considerable demands on the clinicians. We provide here a scholarly practical guide summarising the key concepts to support clinicians with probabilistic prognostic reasoning in the CHR state. We review risk or cumulative incidence of psychosis in, person-time rate of psychosis, Kaplan-Meier estimates of psychosis risk, measures of prognostic accuracy, sensitivity and specificity in receiver operator characteristic curves, positive and negative predictive values, Bayes’ theorem, likelihood ratios, potentials and limits of real-life applications of prognostic probabilistic reasoning in the CHR state. Understanding basic measures used for prognostic probabilistic reasoning is a prerequisite for successfully implementing the early detection and prevention of psychosis in clinical practice. Future refinement of these measures for CHR patients may actually influence risk management, especially as regards initiating or withholding treatment.

INTRODUCTION

Psychoses, in particular schizophrenia, are still one of the most costly and disabling disorders, despite their low incidence of 0.032 per 100 person-years (95% CI from 0.025 to 0.041 per 100 person-years). One cause of poor outcome of psychosis is their often long delay in adequate treatment initiation which his worsening the long-term general symptomatic outcome, positive and negative symptoms, likelihood of remission, social functioning and global outcome. Thus, over the past two decades, increasing efforts have been made to detect and treat psychosis early, preferably already during its prodromal phase of often many years in order to reduce the duration of untreated psychosis and improve the clinical outcomes. To an indicated prevention of psychosis in persons seeking help already for mental problems, two alternative clinical high risk (CHR) approaches to an early detection were developed: (1) the ultra-high risk (UHR) approach including attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms or brief intermittent psychotic symptoms (BLIPS/BIPS) as well as a combination of genetic risk and functional decline (GRFD) and (2) the basic symptom (BS) approach based on subjective, subtle cognitive and perceptive disturbances that form two partly overlapping criteria. Both approaches (BS and UHR) as well as the instruments specifically developed for their assessment have shown the ability to detect a considerably increased CHR for psychosis with pooled 1–3-year conversion rates to psychosis ranging from 15% to 29% for UHR and from 14% to 50% for BS criteria, and sufficient prognostic accuracy of their assessment, in particular in ruling out psychosis risk. However, these figures are not stable but were shown to vary not only with the follow-up time but also with characteristics of the group in which CHR state is assessed, for example, with age composition or main referral source. Thus, when using these CHR criteria or instruments for clinical purposes, the predicted outcome is not a certainty but only a probability; and, consequently, any therapeutic action following the assessment is based on probabilistic prognostic reasoning. We present here a comprehensive guide summarising the basic concepts of probabilistic prognostic reasoning for psychosis prediction, illustrated by practical examples from the real world scenario of high-risk services. We hope this manuscript will be of practical utility for clinicians and clinical researchers interested in the early detection of psychosis.

PROBABILISTIC PROGNOSTIC REASONING

Risk or cumulative incidence of psychosis in CHR samples

As in any preventive approach, the main aim of an indicated prevention is a reduction in the overall morbidity or cumulative incidence of the disease. In case of the early detection of psychosis, the main outcome is therefore defined by the transition risk to frank psychosis from a CHR state. Thereby, cumulative incidence is usually defined as the probability that a particular event, such as occurrence of a particular disease, has occurred within a given period. Synonyms of cumulative incidence include incidence proportion and risk or probability of developing psychosis. It is usually calculated by the following proportion, assuming that all patients with CHR have been followed-up:

$$\text{Risk of psychosis in patients with CHR} = \frac{\text{number of transitions to psychosis during a specified period}}{\text{number of patients with CHR at baseline}}$$

Such probabilities are commonly defined as the likelihood of an event with values ranging from 0 or 0% (no expected occurrence of the event in any case) to 1 or 100% (certain of the occurrence of the event in all cases). However, as the risk of psychosis onset in patients with CHR is the probability that psychosis will occur within a defined period of time and, consequently, heavily depends on the observation time, risk of psychosis in patients with CHR always has to be referred to in terms of a specified follow-up period.

Example A: No consideration of potential dropouts

One hundred patients with CHR were followed-up, first for 1 year and then for another 2, that is, altogether 3 years. At the end of 1 year, 15 patients had developed psychosis.

→ 1-year risk of psychosis = 15/100 = 0.15

At the end of 3 years, 14 further patients had developed psychosis, cumulating to altogether 29 cases with a transition to psychosis within 3 years.

→ 3-year risk of psychosis = (15 + 14)/100 = 0.29
Person-time or incidence rate of psychosis in CHR

Other than risk or cumulative incidence of psychosis that assumes that the outcome of all patients with CHR at the end of the follow-up period is known, the incidence rate or person-time rate is a measure that incorporates the true observation time directly into the denominator. Thus, it can account for the unfortunately likely persons who dropout during longer observation periods. As for the proportion used to compute the cumulative incidence, the numerator of the person-time rate is the number of transitions to psychosis during the follow-up time. However, the denominator is not the baseline number of patients with CHR but the total of the observation time (commonly given in years) of each patients with CHR (see example B below).

Example B. Consideration of potential dropouts

Again, 100 patients with CHR were followed up annually for 3 years. After 1 year, 15 had developed psychosis but 10 were lost to follow-up. After 2 years, 5 had developed psychosis and 5 were additionally lost to follow-up. After 3 years, another 9 had developed psychosis and 10 were lost to follow-up. To calculate the person-time rate of psychosis, we will assume that patients with CHR with psychosis onset and those lost to follow-up were disease-free for 6 months and thus contribute 0.5 years to the denominator.

\[
\text{Person-time rate of psychosis} = \frac{(15 + 5 + 9)(75 + 0.5 \times 15) + (65 + 0.5 \times 5 + 0.5 \times 5) + (55 + 0.5 \times 9 + 0.5 \times 10)}{222} = 0.13 \text{ per persons-years of follow-up}
\]

Thus, the 3-year person-time or incidence rate of psychosis with consideration of individual observation times (\(=3 \times 0.13=0.39\)) is considerably higher than the 3-year cumulative incidence of Example A (\(=0.29\)). This leads to the question, which measure (person-time rate vs cumulative incidence) should followed in clinical practice. Since the cumulative incidence ignores patients lost to follow-up, and conservatively assumes that they remained disease-free over the years, it might actually underestimate the true probability of psychosis transition in CHR samples. Indeed, there is evidence that about 23% of patients with CHR who disengage from CHR services (drop-outs) will later develop psychosis. Thus, in practice, the incidence rate relating to person-years should be preferred over the more conservative cumulative incidence or risk.

Kaplan-Meier estimates of psychosis risk in patients with CHR

An even more accurate time-to-event estimate of risk of psychosis, which also deals with incomplete observations is provided by Kaplan-Meier (survival) curves. A Kaplan-Maier curve is defined as the probability of surviving in a given length of time, thereby considering time in many small intervals. A previous meta-analysis provided a summary Kaplan-Maier estimate of psychosis risk in CHR samples (mainly by UHR criteria), and indicated that most transitions occurred within the first 2 years. Owing to this, it may be clinically relevant to know the exact risk of psychosis onset in patients with CHR, given psychosis will occur during this timeframe (this will apply to most transitions although later transitions are also possible, in particular in CHR samples defined by BS criteria). Time to transition, given transition will occur in the first 2 years, is depicted in figure 1. Such a figure—or rather such a set of figures, considering the impact of type of risk criteria, age, referral source and possibly other patient characteristics—might be of clinical interest because they might be practically used by CHR clinicians to optimise the timing of their prognostic assessments and treatments accordingly (eg, more frequent CHR reassessments in the first 2 years to not miss the chance to adapt treatment to possible symptom exacerbations). Thus, in practice, the incidence rate relating to person-years should be preferred over the more conservative cumulative incidence or risk.

Measures of prognostic accuracy in CHR samples

Next to these risk estimates relating predominately to CHR populations, risk estimates that rather relate to CHR assessments, that is, a test’s accuracy measures, are often used in diagnostic decision-making. These include a range of measures derived from a 2×2 contingency table, cross-classifying the binary result of a CHR assessment and the binary result of the follow-up gold standard assessment of psychosis (table 1), that will be discussed in the following.

Sensitivity and specificity of CHR assessment

In simple terms, the sensitivity of the CHR assessment is defined as the proportion of patients developing psychosis who have a positive CHR assessment result (CHR+). The specificity of a test is the proportion of patients not developing psychosis who have a negative CHR assessment result (CHR−).

Example C: Sensitivity and specificity of a CHR assessment

A total of 150 patients seeking help at a CHR service undergo CHR assessment. One hundred of them are deemed at CHR+ and of these 29 will develop psychosis at 3 years (CHR+T). Among the 50 not considered at risk, that is, CHR−, 2 will develop psychosis at 3 years (CHR−T) and 48 will not (CHR−NT). Thus, sensitivity and specificity of the CHR assessment at 3-year follow-up are:

\[
\text{Sensitivity} = \frac{(CHR+T) \times 100}{(CHR+T + CHR−T)} = \frac{29 \times 100}{(29 + 2)} = 93.5\%
\]

\[
\text{Specificity} = \frac{(CHR−NT) \times 100}{(CHR−NT + CHR+NT)} = \frac{48 \times 100}{(48 + 71)} = 40.3\%
\]

A perfect assessment would have 100% sensitivity and 100% specificity, yet in the likely absence of such perfect values, no clear guidelines to weigh sensitivity against specificity exist but only rules-of-thumb. For example, Sackett suggested to use the test with the highest sensitivity for ‘ruling out’ and that with the highest specificity for ‘ruling in’ the disease, irrespective of the number of false-positive or false-negative classifications. In contrast, balancing severity of the disorder against risk associated with treatment, McNeil et al suggested to use highly sensitive tests, even if of little specificity, when the disorder is
severe but its treatment benign and safe; and highly specific tests, even if of little sensitivity, when treatments carry the risk of severe side-effects and long-term consequences. Furthermore, clinical utility of sensitivity and specificity is limited by the fact that they cannot be directly used to estimate the individual probability of developing psychosis in a patient undergoing CHR assessment. Indeed, high sensitivity and specificity do not ensure that the test will be clinically useful, nor do low sensitivity and specificity render a test useless. Sensitivity and specificity may also be unstable and affected by factors such as sampling bias, small samples, bias in test scores or errors in selection and use of tests.

The sensitivity and specificity of CHR assessments have recently been estimated at meta-analytical level. The prognostic specificity for psychosis prediction at 38 months was 96% (95% CI 92% to 98%), while the prognostic specificity for psychosis prediction at 38 months was 47% (95% CI 38% to 57%). These values indicate that CHR assessments have an outstanding ability to rule out psychosis risk and an only modest ability to rule in subsequent psychosis.

**Sensitivity and specificity in ROC curves**

Sensitivity and specificity at different data points (eg, sum scores) of continuous data can be plotted in the ROC curves. ROC curves plot (1-specificity) of a test on the x-axis against its sensitivity on the y-axis. The area under this curve (AUC) represents the overall accuracy of a test, with values of 0.9–1.0 (equal to 90–100%) considered outstanding, of 0.8–0.9 excellent and of 0.7–0.8 acceptable. The off-diagonal on the graph represents an AUC of 0.5, indicating only random discrimination, that is, a test whose results are no better than tossing a coin. ROC curve for CHR assessment was reported as very good (AUC=0.90; 95% CI 0.87 to 0.93). The performance of a test is quantified in the ROC curves by a number of parameters, namely: pre-test probability, positive likelihood ratio (LR+), negative likelihood ratio (LR−), positive predictive value (PPV), and negative predictive value (NPV).

**Figure 2** Meta-analytical probability modifying plot, illustrating the relationship between pretest probability of psychosis onset at 38 months and post-test probability of psychosis risk at 38 months based on clinical high risk (CHR) psychometric assessment in patients seeking help at high-risk services, computed as the likelihood of a positive (above diagonal line in red; LR+) or negative (below diagonal line in green, LR−) CHR assessment result over the 0–1 range of pretest probability, adapted from. The vertical black line indicates the average pretest probability of psychosis onset in patients referred to high-risk services (15% at 38 months) which yields a 26% post-test probability of psychosis onset in CHR+ cases and a 1.56% post-test probability of psychosis onset at 38 months in CHR− cases. LR, likelihood ratio.

---

**Table 1** Measures of prognostic accuracy that can be calculated from a 2x2 table showing the cross-classification of a CHR assessment and subsequent gold standard assessment of psychosis

<table>
<thead>
<tr>
<th>Population seeking help at CHR services</th>
<th>Psychotic disorder as defined with the gold standard ICD/DSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHR assessment outcome</td>
<td>Developing psychosis</td>
</tr>
<tr>
<td>At Risk (CHR+)</td>
<td>Pretest probability (x-axis in figure 2)</td>
</tr>
<tr>
<td>Not At Risk (CHR−)</td>
<td>Sensitivity</td>
</tr>
<tr>
<td></td>
<td>Specificity</td>
</tr>
<tr>
<td></td>
<td>Positive Predictive Value (PPV)</td>
</tr>
<tr>
<td></td>
<td>Negative predictive value (NPV)</td>
</tr>
<tr>
<td></td>
<td>Accuracy</td>
</tr>
<tr>
<td></td>
<td>Positive likelihood ratio (LR+)</td>
</tr>
<tr>
<td></td>
<td>Negative likelihood ratio (LR−)</td>
</tr>
<tr>
<td></td>
<td>Post-test positive probability (red line in figure 2)</td>
</tr>
<tr>
<td></td>
<td>Post-test negative probability (green line in figure 2)</td>
</tr>
</tbody>
</table>

Pretest probability (x-axis in figure 2) = The probability of developing psychosis before the CHR assessment, also called the prevalence of the disease: (true positive+false negative)/(true positive+false negative+false positive+true negative)

Sensitivity = Proportion of patients who will develop the psychosis who will have a positive CHR assessment result: true positive/(true positive+false negative)

Specificity = The proportion of patients without the development of psychosis who will have a negative CHR assessment result: true negative/(true negative+false positive)

Positive Predictive Value (PPV) = The proportion of patients with a positive CHR assessment result who actually have developed psychosis: true positive/(true positive+false positive)

Negative predictive value (NPV) = The proportion of patients with a negative CHR assessment result who do not have actually developed psychosis: true negative/(true negative+false negative)

Accuracy = The proportion of true results among the total number of CHR patients assessed: true positive+true negative)/(true positive+false positive+false negative+true negative)

Positive likelihood ratio = The probability of a CHR patient who develop psychosis testing positive at the CHR assessment divided by the probability of a person who does not develop the psychosis testing positive at the CHR assessment: sensitivity/(1-specificity)

Negative likelihood ratio = The probability of a patient who develop psychosis testing negative at the CHR assessment divided by the probability of a patient who does not develop psychosis testing negative at the CHR assessment: (1-sensitivity)/specificity

Post-test positive probability (red line in figure 2) = The individual probability of developing the disease given a positive prognostic test result: Pretest probability×Sensitivity/(Pretest probability×Sensitivity)+(1−Pretest probability×Sensitivity))×(1−Specificity)

Post-test negative probability (green line in figure 2) = The individual probability of developing the disease given a negative prognostic test result: (1−Pretest probability)×Specificity/(1−Pretest probability×Specificity)+Pretest probability×(1−Specificity)

APS, attenuated psychosis symptoms; BIPS, brief intermittent psychotic symptoms; BLIPS, brief limited intermittent psychotic symptoms; BS, basic symptoms. Adapted from; CHR, clinical high risk (UHR and/or BS); DSM, Diagnostic and Statistical Manual; GRFD, genetic risk and deterioration syndrome; ICD, International Classification of Diseases; UHR, ultra high risk (including BLIPS/BIPS and/or APS and/or GRFD).
Positive and negative predictive values

Accuracy measures that—other than sensitivity and specificity—are not considered independent of the risk of psychosis in the population to that a particular patient with CHR belongs are the positive and negative predictive values (PPV, NPV). The PPV is the proportion of CHR+ patients who actually have developed psychosis (T), whereas NPV is the proportion of CHR− patients who have not developed psychosis (NT). The PPV of CHR assessment at different time points has been reported in an earlier meta-analysis, indicating a risk of psychosis onset among CHR+ patients between 18% (95% CI 12% to 25%) at 6 months, and 36% (95% CI 24% to 35%) at more than 36 months. Coming back to Example C, a CHR test with 93.5% sensitivity and 40.3% specificity at 3 years, the corresponding risk of psychosis, PPV and NPV are:

- Risk of psychosis the population assessed=\((29+2)\times100/(150-20.7\)\%\)
- PPV=\((29+1)\times100/(29+1+29+71)=29.0\%\)
- NPV=\((29-1)\times100/(29-1+29+71)=96.0\%\)

**Example D: Influence of the population’s risk of psychosis on PPV and NPV**

Let’s now assume we assess CHR in a different population of 973 patients, 591 of whom will test CHR+ and 382 CHR−. Among the CHR+, 29 will develop psychosis (CHR+T) and 562 not (CHR+NT); among those CHR−, 2 would develop psychosis (CHR−T) and 380 not (CHR−NT). Sensitivity and specificity would remain the same, sensitivity 93.5% and specificity 40.3%. However, the prevalence of psychosis risk in the population assessed would be lower, impacting in particular on the PPV:

- Risk of psychosis in the population assessd=\((29+2)\times100/973=3.2\%\)
- PPV=\((29+1)\times100/(29+1+29+71)=4.9\%\)
- NPV=\((29-1)\times100/(29-1+29+71)=99.5\%\)

Although PPV and NPV may be used to estimate the individual probabilities of developing psychosis in CHR patients, their clinical usefulness is restricted to populations whose prevalence of disease is similar to the one from which they were estimated. Recent meta-analyses indicated that the prevalence of psychosis in patients undergoing CHR assessment is of 15%, with high heterogeneity (95% CI 9% to 24%) across individual sites.

Bayes’ theorem and predictive ability of CHR assessment

Ultimately, the value of a test will depend on its ability to alter a pretest probability of a target condition into a post-test probability that will influence a clinical management decision. Pretest and post-test probability of psychosis in CHR patients index an individual’s likelihood of the development of psychosis before and after the CHR assessment, respectively. To be clinically useful, the results of the CHR assessment should substantially change the pretest probability of the individual patient to develop the disease, that is, significantly increase or decrease his/her post-test probability. These concepts are linked to Bayes’ theorem that describes the probability (P) of an event (eg, transition to psychosis, T), based on conditions that might be related to the event (eg, being CHR+). In case of early detection, Bayes’ theorem can be stated mathematically as:

\[ P(T|CHR+) = \frac{P(CHR+|T) \times P(T)}{P(CHR+)} \]

or in words: The conditional probability of development of psychosis given a positive CHR assessment, \(P(T|CHR+)\), is the product of the conditional probability of CHR+ given that psychosis develops, \(P(CHR+|psychosis)\), and the probability of psychosis, \(P(T)\), divided by the probability of a positive CHR assessment, \(P(CHR+)\).

Likelihood ratios

Several authors have suggested the use of positive and negative likelihood ratios (LR+, LR−) instead of sensitivity and specificity to better account for differences in the quality between the two and for pretest probabilities. LRs combine the estimates of sensitivity and specificity and offer the advantage of existing guidelines for their quality assessment. Thereby, LR+ (Sensitivity/(1−Specificity)) (table 1) gives the factor by which the pretest probability increases given a positive test result, while LR− (1−Sensitivity/Specificity) (figure 2) gives the fraction to which the post-test probability decreases given a negative test result.

As a rough guide, LR+ >10 and LR−<0.1 generate large and often diagnostically conclusive changes from pretest to post-test probability; LR+ of 5−10 and LR− of 0.1−0.2 produce moderate shifts in probability; LR+ of 2−5 and LR− of 0.2−0.5 result in small (but sometimes important) changes in probability, while LR+ <2 and LR− >0.5 change probability to a very small (and rarely important) degree. A graphical presentation of LRs with the probability modifying plot (figure 2) can improve the accuracy of estimated post-test disease probability in clinical practice.

In a previous meta-analysis, we have shown that current CHR assessment has an excellent ability to rule out psychosis (LR−=0.09), at the expense of their ability to rule in psychosis (LR+=1.82) and these LRs are reported in figure 2. In fact, given a pretest probability of 15% in patients referred to high-risk services, the LR+=1.82 26 the post-test probability of psychosis onset at 38 months, given a CHR+ assessment is of 26% (95% CI 23% to 30%) and given a CHR− assessment is of 1.56% (95% CI 0.7% to 2.42%).

Assessing psychosis risk in clinical practice: the potentials and pitfalls of real-life application

While LRs thereby offer a good tool for the probabilistic assessment of individual risk, they were shown to be the least well understood accuracy measures by clinicians. Yet, probabilistic reasoning makes considerable demands on the clinician even beyond understanding of LRs, for example, estimating an individual’s pretest risk of psychosis onset based on available, often heterogeneous and fragmented information on population estimates, as roughly illustrated by table 2. However, probabilistic reasoning in CHR has already been very useful in advising clinicians on the use of CHR assessment. As shown in table 2, probabilistic reasoning shows that CHR assessment should be restricted to populations seeking help at high-risk services (case 3) only, to avoid small and negligible PPVs and NPVs (cases 1 and 2). Unfortunately, the pretest probability of psychosis onset in different subsamples (eg, migrants,
Table 2 Description of three hypothetical cases, from real-world scenarios, illustrating the impact of different pretest probabilities of psychosis onset related to potential sampling bias on estimated post-test probabilities of psychosis onset after CHR assessment, computed using the LRs indicated in figure 22

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>General population</td>
<td>Genetic high-risk population</td>
</tr>
<tr>
<td>Setting</td>
<td>School</td>
<td>Relative’s self-support group</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Age</td>
<td>21 years</td>
<td>19 years</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Black Caribbean</td>
<td>White</td>
</tr>
<tr>
<td>Family history of psychosis</td>
<td>No</td>
<td>Mother diagnosed with schizophrenia</td>
</tr>
<tr>
<td>Estimated 3-year risk of psychosis of population</td>
<td>0.27% (assuming an annual incidence of Black Caribbean migrants of 0.001%20)</td>
<td>4% (assuming a 3-year risk of psychosis in offspring of mothers with schizophrenia as estimated from the Kaplan-Meier, figure 2 from1)</td>
</tr>
<tr>
<td>Assessment</td>
<td>Interview (CHR assessment)</td>
<td>Interview (CHR assessment)</td>
</tr>
<tr>
<td>3-year post-test probability in case of positive result</td>
<td>0.49%</td>
<td>7.05%</td>
</tr>
<tr>
<td>(LR + 1.82)20</td>
<td>(LR− 0.09)20</td>
<td></td>
</tr>
<tr>
<td>3-year post-test probability in case of negative result</td>
<td>0.02%</td>
<td>0.38%</td>
</tr>
</tbody>
</table>

CHR, clinical high risk; LR, likelihood ratio.

substance users) of patients seeking help at high-risk services is still not unknown. Thus, future research should overcome the limited pretest probability data29 by providing CHR clinicians with reliable and simple, yet not over-simplistic information on pretest probabilities in different samples seeking help at high-risk services and LRs that is presented in a well-applicable, for example, graphic form and with good guidelines for their use.

CONCLUSIONS

The current reviews illustrated the basic concepts that are necessary for probabilistic reasoning in the CHR state. Understanding basic measures used for prognostic probabilistic reasoning is a prerequisite for probabilistic reasoning in the CHR state. Understanding basic measures used for diagnostic reasoning in the CHR state is still challenging. Understanding basic measures used for diagnostic reasoning in the CHR state is still challenging. Understanding basic measures used for diagnostic reasoning in the CHR state is still challenging. Understanding basic measures used for diagnostic reasoning in the CHR state is still challenging. Understanding basic measures used for diagnostic reasoning in the CHR state is still challenging.

Future refinement of these measures for CHR patients may actually influence risk management, especially as regards initiating or withholding treatment.17

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

doi:10.1136/eb-2015-102295

Received 11 December 2015; Revised 17 December 2015; Accepted 22 December 2015

REFERENCES


